| Primary | The Percentage of Participants With a ≥ 2-grade Improvement From Baseline on the Facial Wrinkle Scale With Photonumeric Guide (FWS) According to INVESTIGATOR AND PARTICIPANT Assessments of LCL Severity at Maximum Smile at Day 30 | The outcome measured is the percentage of participants who had a ≥2-grade improvement from baseline LCL severity at maximum smile according to investigator and participant FWS ratings at Day 30. Both the INVESTIGATOR AND PARTICIPANT evaluate the LCL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe. The primary endpoint is achieved and recorded as a count only when BOTH INVESTIGATOR AND PARTICIPANT assess the improvement in FWS from baseline to be ≥ 2-grade improvement. Therefore, the primary endpoint is the proportion/percentage of participants who meet the dual assessment threshold of ≥2-grade improvement from baseline. | The primary endpoint measurements were carried out using the Intent-To-Treat (ITT) analysis set, which was defined as all participants who were randomized. Multiple imputation method was used for missing variables in primary efficacy endpoint. | Posted | | Count of Participants | | Participants | | Day 30 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Placebo was injected into the Lateral Canthal Lines (LCL) and into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L 24U + Placebo | MT10109L 24U was injected into the Lateral Canthal Lines (LCL) and Placebo into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. . | | OG002 | MT10109L 24U + MT10109L 20U | MT10109L 24U was injected into the Lateral Canthal Lines (LCL) and MT10109L 20U into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Secondary | The Percentage of Responders for INVESTIGATOR Assessments of Lateral Canthal Lines (LCL) Severity at Maximum Smile Using the Facial Wrinkle Scale With Photonumeric Guide (FWS) | The outcome here only considers the INVESTIGATOR assessments (excludes the participant assessment). The investigator evaluates the participant's LCL severity using a 4-point scale (0 to 3) where 0=none and 3=severe. A Responder was defined as one achieving a ≥2-grade improvement from baseline at maximum smile at Day 30. | All secondary efficacy analyses were carried out using the Intent-To-Treat (ITT) analysis subset, which was defined as all participants who were randomized. Analyses of the secondary efficacy variables were performed using observed data. | Posted | | Count of Participants | | Participants | | Day 30 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Placebo was injected into the Lateral Canthal Lines (LCL) and into the Glabellar Line (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L 24U + Placebo | MT10109L 24U was injected into the Lateral Canthal Lines (LCL) and Placebo into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L 24U + MT10109L 20U |
|
| Secondary | The Duration of Lateral Canthal Lines (LCL) Treatment in Participants Who Achieved a Rating of ≥ 2-grade Improvement From Baseline in LCL Severity at Maximum Smile at Day 30 According to Investigator Assessments Using the FWS | The investigator evaluates the participant's LCL severity using a 4-grade scale (0 to 3) where 0=none and 3 = severe. | All secondary efficacy analyses were carried out using the Intent-To-Treat (ITT) analysis subset, which was defined as all participants who were randomized. Analyses of the secondary efficacy variables were performed using observed data. The participant analyzed here corresponds to the responders in Outcome 2. | Posted | | Median | 95% Confidence Interval | Days | | Day 1 (first treatment) to Day 180 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Placebo was injected into the LCL and into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L 24U + Placebo | MT10109L 24U was injected into the LCL and Placebo into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L 24U + MT10109L 20U | MT10109L 24U was injected into the LCL and MT10109L 20U into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. |
|
| Secondary | The Percentage of Participants Reporting Mostly Satisfied/Very Satisfied on the Facial Line Satisfaction Questionnaire (FLSQ) Follow-up Version Item 5 for Lateral Canthal Lines (LCL) | The Satisfaction Question 5 grades facial line treatment satisfaction on a 5-point scale (-2 to 2) where -2=Very dissatisfied and 2=Very satisfied. | All secondary efficacy analyses were carried out using the Intent-To-Treat (ITT) analysis set or subset, which was defined as all participants who were randomized. Analyses of the secondary efficacy variables were performed using observed data. | Posted | | Count of Participants | | Participants | | Day 60 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Placebo was injected into the Lateral Canthal Lines (LCL) and into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L 24U + Placebo | MT10109L 24U was injected into the Lateral Canthal Lines (LCL) and Placebo into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L 24U + MT10109L 20U | MT10109L 24U was injected into the Lateral Canthal Lines (LCL) and MT10109L 20U into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. |
|
| Secondary | The Percentage of Responders for Investigator Assessments of Lateral Canthal Lines (LCL) Severity at Rest Using the Facial Wrinkle Scale (FWS) | The investigator evaluates the participant's LCL severity using a 4-point scale (0 to 3) where 0=none and 3=severe. Among Participants Who Were Rated At least Mild at Rest at Baseline, where a Responder was Defined as Achieving a ≥1-grade Improvement from Baseline at Day 30. The outcome measured here is the proportion of participants who achieved a ≥1-grade improvement from baseline LCL severity at rest based on investigator FWS rating. | All secondary efficacy analyses were carried out using the Intent-To-Treat (ITT) analysis subset, which was defined as all participants who were randomized. Analyses of the secondary efficacy variables were performed using observed data. | Posted | | Count of Participants | | Participants | | Day 30 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Placebo was injected into the Lateral Canthal Lines (LCL) and into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L 24U + Placebo | MT10109L 24U was injected into the Lateral Canthal Lines (LCL) and Placebo into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | |
|
| Secondary | Number of Patients Who Experienced a Treatment Emergent Adverse Event (TEAEs) | This section focuses primarily on TEAEs, i.e., AEs that started or worsened after the first dose of study intervention and within 30 days after the last dose. The safety analyses were conducted in the Safety population. Unless otherwise noted, safety results refer to TEAEs. | All safety analyses were carried out using the Safety population set or subset, defined as participants who received at least 1 dose of study intervention. Participants were grouped based on their actual treatment received. | Posted | | Count of Participants | | Participants | | AEs that started or worsen after the first dose of study intervention and within 30 days after the last dose. | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Placebo was injected into the LCL and into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L 24U + Placebo | MT10109L 24U was injected into the LCL and Placebo into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L 24U + MT10109L 20U | MT10109L 24U was injected into the LCL and MT10109L 20U into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. |
|
| Secondary | Mean Change From Baseline in Systolic Blood Pressure (BP) | The outcome reported here is the mean change in Systolic BP from baseline to study exit. | The population analyzed for this outcome was the subset of participants from the Safety population remaining at study exit. Participants were grouped based on their actual treatment received. | Posted | | Mean | Standard Deviation | mmHg | | Baseline to Day 360 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Placebo was injected into the Lateral Canthal Lines (LCL) and into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L 24U + Placebo | MT10109L 24U was injected into the Lateral Canthal Lines (LCL) and Placebo into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L 24U + MT10109L 20U | MT10109L 24U was injected into the Lateral Canthal Lines (LCL) and MT10109L 20U into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. |
|
| Secondary | Mean Change From Baseline in Diastolic Blood Pressure (BP) | The outcome reported here is the mean change in Diastolic BP from baseline to study exit. | The population analyzed for this outcome was the subset of participants from the Safety population remaining at study exit. Participants were grouped based on their actual treatment received. | Posted | | Mean | Standard Deviation | mmHg | | Baseline to Day 360 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Placebo was injected into the Lateral Canthal Lines (LCL) and into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L 24U + Placebo | MT10109L 24U was injected into the Lateral Canthal Lines (LCL) and Placebo into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L 24U + MT10109L 20U | MT10109L 24U was injected into the Lateral Canthal Lines (LCL) and MT10109L 20U into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. |
|
| Secondary | Mean Change From Baseline in Pulse Rate | The outcome reported here is the mean change in Pulse Rate from baseline to study exit. | The population analyzed for this outcome was the subset of participants from the Safety population remaining at study exit. Participants were grouped based on their actual treatment received. | Posted | | Mean | Standard Deviation | beats/min | | Baseline to Day 360 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Placebo was injected into the Lateral Canthal Lines (LCL) and into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L 24U + Placebo | MT10109L 24U was injected into the Lateral Canthal Lines (LCL) and Placebo into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L 24U + MT10109L 20U | MT10109L 24U was injected into the Lateral Canthal Lines (LCL) and MT10109L 20U into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. |
|
| Secondary | Mean Change From Baseline in Respiratory Rate | The outcome reported here is the mean change in Respiratory Rate from baseline to study exit. | The population analyzed for this outcome was the subset of participants from the Safety population remaining at study exit. Participants were grouped based on their actual treatment received. | Posted | | Mean | Standard Deviation | breaths/min | | Baseline to Day 360 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Placebo was injected into the Lateral Canthal Lines (LCL) and into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L 24U + Placebo | MT10109L 24U was injected into the Lateral Canthal Lines (LCL) and Placebo into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L 24U + MT10109L 20U | MT10109L 24U was injected into the Lateral Canthal Lines (LCL) and MT10109L 20U into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. |
|
| Secondary | Mean Change From Baseline in Electrocardiogram (ECG) Parameters - Mean Heart Rate | The outcome reported here is a mean change in mean heart rate from baseline to study exit. | The population analyzed for this outcome was the subset of participants from the Safety population remaining at study exit. Participants were grouped based on their actual treatment received. | Posted | | Mean | Standard Deviation | beats/min | | Baseline to Day 360 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Placebo was injected into the Lateral Canthal Lines (LCL) and into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L 24U + Placebo | MT10109L 24U was injected into the LCL and Placebo into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L 24U + MT10109L 20U | MT10109L 24U was injected into the LCL and MT10109L 20U into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. |
| |
| Secondary | Mean Change From Baseline in Electrocardiogram (ECG) Parameters - PR Interval | The outcome reported here is a mean change in PR interval from baseline to study exit. | The population analyzed for this outcome was the subset of participants from the Safety population remaining at study exit. Participants were grouped based on their actual treatment received. | Posted | | Mean | Standard Deviation | milliseconds | | Baseline to Day 360 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Placebo was injected into the Lateral Canthal Lines (LCL) and into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L 24U + Placebo | MT10109L 24U was injected into the LCL and Placebo into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L 24U + MT10109L 20U | MT10109L 24U was injected into the LCL and MT10109L 20U into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. |
| |
| Secondary | Mean Change From Baseline in Electrocardiogram (ECG) Parameters - QRS Duration | The outcome reported here is a mean change in QRS duration from baseline to study exit. | The population analyzed for this outcome was the subset of participants from the Safety population remaining at study exit. Participants were grouped based on their actual treatment received. | Posted | | Mean | Standard Deviation | milliseconds | | Baseline to Day 360 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Placebo was injected into the Lateral Canthal Lines (LCL) and into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L 24U + Placebo | MT10109L 24U was injected into the LCL and Placebo into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L 24U + MT10109L 20U | MT10109L 24U was injected into the LCL and MT10109L 20U into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. |
| |
| Secondary | Mean Change From Baseline in Electrocardiogram (ECG) Parameters - QT Interval | The outcome reported here is a mean change in QT interval from baseline to study exit. | The population analyzed for this outcome was the subset of participants from the Safety population remaining at study exit. Participants were grouped based on their actual treatment received. | Posted | | Mean | Standard Deviation | milliseconds | | Baseline to Day 360 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Placebo was injected into the Lateral Canthal Lines (LCL) and into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L 24U + Placebo | MT10109L 24U was injected into the LCL and Placebo into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L 24U + MT10109L 20U | MT10109L 24U was injected into the LCL and MT10109L 20U into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. |
| |
| Secondary | Mean Change From Baseline in Electrocardiogram (ECG) Parameters - QTcB Interval | The outcome reported here is a mean change in QTcB interval from baseline to study exit. | The population analyzed for this outcome was the subset of participants from the Safety population remaining at study exit. Participants were grouped based on their actual treatment received. | Posted | | Mean | Standard Deviation | milliseconds | | Baseline to Day 360 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Placebo was injected into the Lateral Canthal Lines (LCL) and into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L 24U + Placebo | MT10109L 24U was injected into the LCL and Placebo into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L 24U + MT10109L 20U | MT10109L 24U was injected into the LCL and MT10109L 20U into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. |
| |
| Secondary | Mean Change From Baseline in Electrocardiogram (ECG) Parameters - QTcF Interval | The outcome reported here is a mean change in QTcF interval from baseline to study exit. | The population analyzed for this outcome was the subset of participants from the Safety population remaining at study exit. Participants were grouped based on their actual treatment received. | Posted | | Mean | Standard Deviation | milliseconds | | Baseline to Day 360 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Placebo was injected into the Lateral Canthal Lines (LCL) and into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L 24U + Placebo | MT10109L 24U was injected into the LCL and Placebo into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L 24U + MT10109L 20U | MT10109L 24U was injected into the LCL and MT10109L 20U into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. |
| |
| Secondary | Mean Change From Baseline in Electrocardiogram (ECG) Parameters - RR Interval | The outcome reported here is a mean change in RR interval from baseline to study exit. | The population analyzed for this outcome was the subset of participants from the Safety population remaining at study exit. Participants were grouped based on their actual treatment received. | Posted | | Mean | Standard Deviation | milliseconds | | Baseline to Day 360 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Placebo was injected into the Lateral Canthal Lines (LCL) and into the Glabellar Lines (GL): initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L 24U + Placebo | MT10109L 24U was injected into the LCL and Placebo into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L 24U + MT10109L 20U | MT10109L 24U was injected into the LCL and MT10109L 20U into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. |
| |
| Secondary | Number of Participants With Binding and Neutralizing Antibodies | Only samples that tested positive in the binding antibody confirmatory assay were evaluated for neutralizing antibodies. The participants with positive neutralizing antibodies are only shown. | The population analyzed for this outcome was the subset of participants from the Safety population remaining at study exit. Participants were grouped based on their actual treatment received. | Posted | | Count of Participants | | Participants | | Baseline to Day 360 | | | | ID | Title | Description |
|---|
| OG000 | Placebo | Placebo was injected into the LCL and into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG001 | MT10109L 24U + Placebo | MT10109L 24U was injected into the LCL and Placebo into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. | | OG002 | MT10109L 24U + MT10109L 20U | MT10109L 24U was injected into the LCL and MT10109L 20U into the GL: initial double-blind treatment on Day 1, and up to 2 additional blinded treatments during the retreatment period. |
|